RE: AVA610316 Oct 2024 22:18
Thanks LLnP.
(https://pmc.ncbi.nlm.nih.gov/articles/PMC10208276/)
An approach toward obtaining longer-lived TOP1i that actively target specific tumors is to incorporate them as payloads in antibody–drug conjugates (ADC). Indeed, three ADCs containing TOP1is—the Trop2-directed sacituzumab govitecan (Trodelvy) delivering SN-38, the HER2-targeted trastuzumab deruxtecan (Enhertu), and Trop2-directed datopotamab deruxtecan delivering a close derivative of Exa—show impressive results in the clinic and have been approved (13). However, most tumors do not have the Trop2 or HER2 surface antigens recognized by these ADCs, and are thus not suitable targets for these tumor-targeted agents. Likewise, ADCs cannot specifically target subsets of a tumor that differs from others in a TOP1i DDR defect, such as BRCA or ATM deficiency. Thus, a need remains to develop long-acting, tumor-agnostic TOP1i prodrugs that do not require the presence of specific tumor antigens to express their antitumor effects.
Enter ava6103.